We are pleased to welcome David Epstein and Todd Simpson to our board of directors. Both have proven track records in the life sciences industry and their experience and expertise will be invaluable in further solidifying our position as a leader in AI for genomic medicine. #Leadership #Innovation #AI #GenomicMedicine #Biotech https://lnkd.in/gEBfg6Aw
Shape Therapeutics Inc.
Biotechnology Research
Seattle, Washington 10,582 followers
The future of programmable RNA Medicines
About us
ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and disruptive gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more.
- Website
-
http://www.shapetx.com
External link for Shape Therapeutics Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Seattle, Washington
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Gene Editing, Gene Therapy, and RNA Editing
Locations
-
Primary
Get directions
219 Terry Ave N
Seattle, Washington 98109, US
Employees at Shape Therapeutics Inc.
Updates
-
Shape's Head of AI Ron Hause had a great conversation with Benchling about implementing AI in Biotech https://lnkd.in/gt-FGWbM
Lessons from Shape Therapeutics: How to harness AI for R&D success | Benchling
benchling.com
-
Amazing work from the Shape scientific team! Achieving >90% Editing in Mouse and Non-Human Primate Brain with the RNAfix platform https://lnkd.in/gGYyH7wJ
Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brain
globenewswire.com
-
ShapeTX is once again taking over Union Square for #jpm2024! Look out for our kiosk ads throughout the area and visit ShapeTX.com to learn more about our work in engineering programmable medicines!
-
-
Heading to the JP Morgan Healthcare Conference next week? Meet with us onsite to learn more about our work creating programmable medicines with AI and RNA! Reach out via our contact form to set up a meeting: https://bit.ly/47mT99A
-
-
Calling all JPM Healthcare Conference attendees - join our VP of Process and Product Development, Ken Prentice as he moderates a panel on next-generation gene therapy for GenScript's Biotech Global Forum on Jan 10 at 3:20 PM! Tickets available here: https://bit.ly/3S6yu4b
GenScript Biotech Global Forum
eventbrite.hk
-
Our latest news update was an expansion of our partnership with Roche. In December, Roche added an additional target by utilizing our AI-powered RNAfix™ platform. What a great way to close out 2023! Read about this and other ShapeTX news via Fierce Biotech: https://bit.ly/3R1l4pw
Phenomic AI inks second deal in two days, Shape stretches Roche collab
fiercebiotech.com
-
ShapeTX has enjoyed many great successes in 2023 thanks to our partners. In October we announced our collaboration with Otsuka Pharmaceutical Co., Ltd. to apply our generative AI and AAVid™ capsid discovery platform with Otsuka’s expertise in ocular diseases to create novel treatment options for patients. https://bit.ly/3ZjG1je
Otsuka's eye disease strategy takes Shape with $1.5B biobucks deal
fiercebiotech.com